GSK's experimental asthma drug, depemokimab, significantly reduced severe attacks in late-stage trials.
GSK's experimental drug, depemokimab, reduced severe asthma attacks in late-stage trials, showing promise for a treatment that could exceed £3 billion in sales. Depemokimab reduced severe asthma exacerbations in patients with eosinophilic asthma over 52 weeks and targets a cytokine that spurs eosinophil activation. If approved, it could be the first ultra-long-acting biologic with a six-month dosing schedule for severe asthma patients.
May 21, 2024
7 Articles